NASDAQ:QNCX | Free Cash Flow | Quince Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2018-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$7.63M$0.00-$7.63M-21.24%
2025-12-31-$10.48M$4,000.00-$10.49M
2025-03-31-$9.6M$148,000.00-$9.75M
2024-12-31-$7.55M$133,000.00-$7.69M
2024-03-31-$8.35M$39,000.00-$8.39M
2023-12-31-$6.08M$24,000.00-$6.1M
2023-03-31-$3.57M$136,000.00-$3.71M
2022-12-31-$5.84M$78,000.00-$5.91M
2022-03-31-$16.09M$5,000.00-$16.1M
2021-12-31-$14.42M$44,000.00-$14.46M
2021-03-31-$13.61M$37,000.00-$13.65M
2020-12-31-$13.28M$10,000.00-$13.29M
2020-03-31-$10.78M$5,000.00-$10.78M
2019-12-31-$10.95M$9,000.00-$10.96M
2019-03-31-$7.22M$51,000.00-$7.27M
2018-12-31-$3.97M$0.00-$3.97M
2018-03-31-$3.18M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$41.43M$352,000.00-$41.78M
2024-12-31-$31.9M$257,000.00-$32.16M
2023-12-31-$18.29M$160,000.00-$18.45M
2022-12-31-$44.04M$133,000.00-$44.17M
2021-12-31-$62.93M$180,000.00-$63.11M
2020-12-31-$50.82M$52,000.00-$50.87M
2019-12-31-$33.28M$55,000.00-$33.33M
2018-12-31-$11.7M$212,000.00-$11.91M